Dose extension

Phase 1Biologic

IInstitute of Hematology & Blood Diseases Hospital, China

Dose extension is one of 74 biologic programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Ovarian CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 1

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

8 2

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 3

Liposomal Doxorubicin

Eli Lilly

Phase 3

9 4

Cediranib

AstraZeneca

Phase 3

6 5

Tylenol

KKenvue Brands

Phase 3

1 6

Trastuzumab Deruxtecan

AstraZeneca

Phase 3

1 7

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

3 8

Single Dose of

Boehringer Ingelheim

Phase 3

1 9

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

2 10

JSKN003

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Esophageal Squamous Cell Carcinoma

NCT06690476

Q1 2028

Phase 1Recruiting

Hematopoietic Stem Cell Transplantation

NCT06792682

Q4 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06464055

Clinical

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06792682·15 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

Recruiting·PPeking University·Phase 1·NCT06690476·74 enrolled

HIV-11 trial

Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load

Completed·UUniversity of Liverpool·Phase 2/3·NCT04121195·26 enrolled

Advanced Solid Tumors1 trial

A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting·GGeneQuantum Healthcare (Suzhou) Co., Ltd.·Phase 1/2·NCT06464055·260 enrolled

Ovarian Cancer1 trial

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT03944902·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Dose extension. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dose extension compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dose extension. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

Dose extension

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q4 2028

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

Esophageal Squamous Cell Carcinoma1 trial

HIV-11 trial

Advanced Solid Tumors1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News